Clinical correlation to differences in ranibizumab and aflibercept vascular endothelial growth factor suppression times
AimTo determine clinical correlations to intraocular vascular endothelial growth factor A (VEGF-A) suppression times (VSTs) on the treatment of neovascular age-related macular degeneration (nAMD) with ranibizumab (Lucentis) or aflibercept (Eylea).MethodsSeven of 89 treatment-naïve nAMD eyes showed p...
Gespeichert in:
| Veröffentlicht in: | British journal of ophthalmology 2016-11, Vol.100 (11), p.1494-1498 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1498 |
|---|---|
| container_issue | 11 |
| container_start_page | 1494 |
| container_title | British journal of ophthalmology |
| container_volume | 100 |
| creator | Fauser, Sascha Muether, Philipp S |
| description | AimTo determine clinical correlations to intraocular vascular endothelial growth factor A (VEGF-A) suppression times (VSTs) on the treatment of neovascular age-related macular degeneration (nAMD) with ranibizumab (Lucentis) or aflibercept (Eylea).MethodsSeven of 89 treatment-naïve nAMD eyes showed persistent choroidal neovascular membrane (CNV) activity throughout a spectral domain optical coherence tomography (SD-OCT)-driven pro re nata (PRN) regimen of intravitreal ranibizumab injections over 28±4 months. The treatment was switched to PRN aflibercept injections and patients were followed for another 15±2 months. A total of 160 aqueous humour specimens were collected before the intravitreal injections, and their VEGF-A concentrations were assayed by Luminex multiplex bead analysis (Luminex, Austin, Texas, USA). Intraocular VEGF-A concentrations were correlated to CNV activity shown by SD-OCT.ResultsThe mean duration of suppression of VEGF-A concentrations in aqueous humour below the lower limit of quantification of our assay was 34±5 (26–69) days for ranibizumab and 67±14 (49–89) days for aflibercept (p |
| doi_str_mv | 10.1136/bjophthalmol-2015-308264 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1826649634</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4236021111</sourcerecordid><originalsourceid>FETCH-LOGICAL-b453t-f8f5658c8ea9efa0b78b85fd510757b0bab3318febaef185a55a32da1c8830e33</originalsourceid><addsrcrecordid>eNqNkcFuFSEUhonR2NvaVzAkbtyMwjAMzNLcWDVp4sauJwfm0MsNAyPM2OjTl3qraVy5OuHk-38IHyGUs3eci_69OablsB4gzCk0LeOyEUy3ffeM7HjX67pSw3OyY4yphvOen5HzUo712PZcvSRnba-1HpTckbt98NFbCNSmnDHA6lOka6KTdw4zRouF-kgzRG_8r20GQyFOFFzwBrPFZaU_oNgtQKYYp7QeMPhad5vT3XqgDuyaMi3bsmQs5Xe5n7G8Ii8chIKXj_OC3Fx9_Lb_3Fx__fRl_-G6MZ0Ua-O0k73UViMM6IAZpY2WbpKcKakMM2CE4NqhAXRcS5ASRDsBt1oLhkJckLen3iWn7xuWdZx9sRgCRExbGXn9tr4betFV9M0_6DFtOdbXVUp0ehBKqUrpE2VzKiWjG5fsZ8g_R87GBznjUznjg5zxJKdGXz9esJkZp7_BPzYqIE6AmY__X3sPFJSi8A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1834893777</pqid></control><display><type>article</type><title>Clinical correlation to differences in ranibizumab and aflibercept vascular endothelial growth factor suppression times</title><source>MEDLINE</source><source>BMJ Journals - NESLi2</source><source>PubMed Central</source><creator>Fauser, Sascha ; Muether, Philipp S</creator><creatorcontrib>Fauser, Sascha ; Muether, Philipp S</creatorcontrib><description>AimTo determine clinical correlations to intraocular vascular endothelial growth factor A (VEGF-A) suppression times (VSTs) on the treatment of neovascular age-related macular degeneration (nAMD) with ranibizumab (Lucentis) or aflibercept (Eylea).MethodsSeven of 89 treatment-naïve nAMD eyes showed persistent choroidal neovascular membrane (CNV) activity throughout a spectral domain optical coherence tomography (SD-OCT)-driven pro re nata (PRN) regimen of intravitreal ranibizumab injections over 28±4 months. The treatment was switched to PRN aflibercept injections and patients were followed for another 15±2 months. A total of 160 aqueous humour specimens were collected before the intravitreal injections, and their VEGF-A concentrations were assayed by Luminex multiplex bead analysis (Luminex, Austin, Texas, USA). Intraocular VEGF-A concentrations were correlated to CNV activity shown by SD-OCT.ResultsThe mean duration of suppression of VEGF-A concentrations in aqueous humour below the lower limit of quantification of our assay was 34±5 (26–69) days for ranibizumab and 67±14 (49–89) days for aflibercept (p<0.001). The percentual reduction of central retinal volume (CRV) 6 weeks after injection was higher for aflibercept compared with ranibizumab (p=0.009). The time point of clinical re-activity occurred about 50% earlier than the respective VST for each ranibizumab and aflibercept.ConclusionsThe VST under aflibercept treatment exceeded that under ranibizumab treatment by a factor of 2. This difference correlated with differential clinical CRV reduction 6 weeks after the respective injection. For both medications, clinical activity was found at a time point as early as 50% of the individual VST.Trial registration numberNCT01213667, post-results</description><identifier>ISSN: 0007-1161</identifier><identifier>EISSN: 1468-2079</identifier><identifier>DOI: 10.1136/bjophthalmol-2015-308264</identifier><identifier>PMID: 26888975</identifier><identifier>CODEN: BJOPAL</identifier><language>eng</language><publisher>England: BMJ Publishing Group LTD</publisher><subject>Aged ; Aged, 80 and over ; Angiogenesis Inhibitors - administration & dosage ; Aqueous Humor - metabolism ; Choroidal Neovascularization - diagnosis ; Choroidal Neovascularization - drug therapy ; Choroidal Neovascularization - metabolism ; Female ; Follow-Up Studies ; Humans ; Intravitreal Injections ; Male ; Middle Aged ; Prospective Studies ; Ranibizumab - administration & dosage ; Receptors, Vascular Endothelial Growth Factor - administration & dosage ; Recombinant Fusion Proteins - administration & dosage ; Time Factors ; Tomography, Optical Coherence ; Treatment Outcome ; Vascular Endothelial Growth Factor A - antagonists & inhibitors ; Vascular Endothelial Growth Factor A - metabolism ; Visual Acuity</subject><ispartof>British journal of ophthalmology, 2016-11, Vol.100 (11), p.1494-1498</ispartof><rights>Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing</rights><rights>Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.</rights><rights>Copyright: 2016 Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b453t-f8f5658c8ea9efa0b78b85fd510757b0bab3318febaef185a55a32da1c8830e33</citedby><cites>FETCH-LOGICAL-b453t-f8f5658c8ea9efa0b78b85fd510757b0bab3318febaef185a55a32da1c8830e33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttp://bjo.bmj.com/content/100/11/1494.full.pdf$$EPDF$$P50$$Gbmj$$H</linktopdf><linktohtml>$$Uhttp://bjo.bmj.com/content/100/11/1494.full$$EHTML$$P50$$Gbmj$$H</linktohtml><link.rule.ids>114,115,314,780,784,3196,23571,27924,27925,77600,77631</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26888975$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fauser, Sascha</creatorcontrib><creatorcontrib>Muether, Philipp S</creatorcontrib><title>Clinical correlation to differences in ranibizumab and aflibercept vascular endothelial growth factor suppression times</title><title>British journal of ophthalmology</title><addtitle>Br J Ophthalmol</addtitle><description>AimTo determine clinical correlations to intraocular vascular endothelial growth factor A (VEGF-A) suppression times (VSTs) on the treatment of neovascular age-related macular degeneration (nAMD) with ranibizumab (Lucentis) or aflibercept (Eylea).MethodsSeven of 89 treatment-naïve nAMD eyes showed persistent choroidal neovascular membrane (CNV) activity throughout a spectral domain optical coherence tomography (SD-OCT)-driven pro re nata (PRN) regimen of intravitreal ranibizumab injections over 28±4 months. The treatment was switched to PRN aflibercept injections and patients were followed for another 15±2 months. A total of 160 aqueous humour specimens were collected before the intravitreal injections, and their VEGF-A concentrations were assayed by Luminex multiplex bead analysis (Luminex, Austin, Texas, USA). Intraocular VEGF-A concentrations were correlated to CNV activity shown by SD-OCT.ResultsThe mean duration of suppression of VEGF-A concentrations in aqueous humour below the lower limit of quantification of our assay was 34±5 (26–69) days for ranibizumab and 67±14 (49–89) days for aflibercept (p<0.001). The percentual reduction of central retinal volume (CRV) 6 weeks after injection was higher for aflibercept compared with ranibizumab (p=0.009). The time point of clinical re-activity occurred about 50% earlier than the respective VST for each ranibizumab and aflibercept.ConclusionsThe VST under aflibercept treatment exceeded that under ranibizumab treatment by a factor of 2. This difference correlated with differential clinical CRV reduction 6 weeks after the respective injection. For both medications, clinical activity was found at a time point as early as 50% of the individual VST.Trial registration numberNCT01213667, post-results</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Angiogenesis Inhibitors - administration & dosage</subject><subject>Aqueous Humor - metabolism</subject><subject>Choroidal Neovascularization - diagnosis</subject><subject>Choroidal Neovascularization - drug therapy</subject><subject>Choroidal Neovascularization - metabolism</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Intravitreal Injections</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Prospective Studies</subject><subject>Ranibizumab - administration & dosage</subject><subject>Receptors, Vascular Endothelial Growth Factor - administration & dosage</subject><subject>Recombinant Fusion Proteins - administration & dosage</subject><subject>Time Factors</subject><subject>Tomography, Optical Coherence</subject><subject>Treatment Outcome</subject><subject>Vascular Endothelial Growth Factor A - antagonists & inhibitors</subject><subject>Vascular Endothelial Growth Factor A - metabolism</subject><subject>Visual Acuity</subject><issn>0007-1161</issn><issn>1468-2079</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqNkcFuFSEUhonR2NvaVzAkbtyMwjAMzNLcWDVp4sauJwfm0MsNAyPM2OjTl3qraVy5OuHk-38IHyGUs3eci_69OablsB4gzCk0LeOyEUy3ffeM7HjX67pSw3OyY4yphvOen5HzUo712PZcvSRnba-1HpTckbt98NFbCNSmnDHA6lOka6KTdw4zRouF-kgzRG_8r20GQyFOFFzwBrPFZaU_oNgtQKYYp7QeMPhad5vT3XqgDuyaMi3bsmQs5Xe5n7G8Ii8chIKXj_OC3Fx9_Lb_3Fx__fRl_-G6MZ0Ua-O0k73UViMM6IAZpY2WbpKcKakMM2CE4NqhAXRcS5ASRDsBt1oLhkJckLen3iWn7xuWdZx9sRgCRExbGXn9tr4betFV9M0_6DFtOdbXVUp0ehBKqUrpE2VzKiWjG5fsZ8g_R87GBznjUznjg5zxJKdGXz9esJkZp7_BPzYqIE6AmY__X3sPFJSi8A</recordid><startdate>20161101</startdate><enddate>20161101</enddate><creator>Fauser, Sascha</creator><creator>Muether, Philipp S</creator><general>BMJ Publishing Group LTD</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20161101</creationdate><title>Clinical correlation to differences in ranibizumab and aflibercept vascular endothelial growth factor suppression times</title><author>Fauser, Sascha ; Muether, Philipp S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b453t-f8f5658c8ea9efa0b78b85fd510757b0bab3318febaef185a55a32da1c8830e33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Angiogenesis Inhibitors - administration & dosage</topic><topic>Aqueous Humor - metabolism</topic><topic>Choroidal Neovascularization - diagnosis</topic><topic>Choroidal Neovascularization - drug therapy</topic><topic>Choroidal Neovascularization - metabolism</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Intravitreal Injections</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Prospective Studies</topic><topic>Ranibizumab - administration & dosage</topic><topic>Receptors, Vascular Endothelial Growth Factor - administration & dosage</topic><topic>Recombinant Fusion Proteins - administration & dosage</topic><topic>Time Factors</topic><topic>Tomography, Optical Coherence</topic><topic>Treatment Outcome</topic><topic>Vascular Endothelial Growth Factor A - antagonists & inhibitors</topic><topic>Vascular Endothelial Growth Factor A - metabolism</topic><topic>Visual Acuity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fauser, Sascha</creatorcontrib><creatorcontrib>Muether, Philipp S</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>British journal of ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fauser, Sascha</au><au>Muether, Philipp S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical correlation to differences in ranibizumab and aflibercept vascular endothelial growth factor suppression times</atitle><jtitle>British journal of ophthalmology</jtitle><addtitle>Br J Ophthalmol</addtitle><date>2016-11-01</date><risdate>2016</risdate><volume>100</volume><issue>11</issue><spage>1494</spage><epage>1498</epage><pages>1494-1498</pages><issn>0007-1161</issn><eissn>1468-2079</eissn><coden>BJOPAL</coden><abstract>AimTo determine clinical correlations to intraocular vascular endothelial growth factor A (VEGF-A) suppression times (VSTs) on the treatment of neovascular age-related macular degeneration (nAMD) with ranibizumab (Lucentis) or aflibercept (Eylea).MethodsSeven of 89 treatment-naïve nAMD eyes showed persistent choroidal neovascular membrane (CNV) activity throughout a spectral domain optical coherence tomography (SD-OCT)-driven pro re nata (PRN) regimen of intravitreal ranibizumab injections over 28±4 months. The treatment was switched to PRN aflibercept injections and patients were followed for another 15±2 months. A total of 160 aqueous humour specimens were collected before the intravitreal injections, and their VEGF-A concentrations were assayed by Luminex multiplex bead analysis (Luminex, Austin, Texas, USA). Intraocular VEGF-A concentrations were correlated to CNV activity shown by SD-OCT.ResultsThe mean duration of suppression of VEGF-A concentrations in aqueous humour below the lower limit of quantification of our assay was 34±5 (26–69) days for ranibizumab and 67±14 (49–89) days for aflibercept (p<0.001). The percentual reduction of central retinal volume (CRV) 6 weeks after injection was higher for aflibercept compared with ranibizumab (p=0.009). The time point of clinical re-activity occurred about 50% earlier than the respective VST for each ranibizumab and aflibercept.ConclusionsThe VST under aflibercept treatment exceeded that under ranibizumab treatment by a factor of 2. This difference correlated with differential clinical CRV reduction 6 weeks after the respective injection. For both medications, clinical activity was found at a time point as early as 50% of the individual VST.Trial registration numberNCT01213667, post-results</abstract><cop>England</cop><pub>BMJ Publishing Group LTD</pub><pmid>26888975</pmid><doi>10.1136/bjophthalmol-2015-308264</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-1161 |
| ispartof | British journal of ophthalmology, 2016-11, Vol.100 (11), p.1494-1498 |
| issn | 0007-1161 1468-2079 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1826649634 |
| source | MEDLINE; BMJ Journals - NESLi2; PubMed Central |
| subjects | Aged Aged, 80 and over Angiogenesis Inhibitors - administration & dosage Aqueous Humor - metabolism Choroidal Neovascularization - diagnosis Choroidal Neovascularization - drug therapy Choroidal Neovascularization - metabolism Female Follow-Up Studies Humans Intravitreal Injections Male Middle Aged Prospective Studies Ranibizumab - administration & dosage Receptors, Vascular Endothelial Growth Factor - administration & dosage Recombinant Fusion Proteins - administration & dosage Time Factors Tomography, Optical Coherence Treatment Outcome Vascular Endothelial Growth Factor A - antagonists & inhibitors Vascular Endothelial Growth Factor A - metabolism Visual Acuity |
| title | Clinical correlation to differences in ranibizumab and aflibercept vascular endothelial growth factor suppression times |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T05%3A05%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20correlation%20to%20differences%20in%20ranibizumab%20and%20aflibercept%20vascular%20endothelial%20growth%20factor%20suppression%20times&rft.jtitle=British%20journal%20of%20ophthalmology&rft.au=Fauser,%20Sascha&rft.date=2016-11-01&rft.volume=100&rft.issue=11&rft.spage=1494&rft.epage=1498&rft.pages=1494-1498&rft.issn=0007-1161&rft.eissn=1468-2079&rft.coden=BJOPAL&rft_id=info:doi/10.1136/bjophthalmol-2015-308264&rft_dat=%3Cproquest_cross%3E4236021111%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1834893777&rft_id=info:pmid/26888975&rfr_iscdi=true |